News Archives - Page 2 of 3

FACIT and T-CAIREM at the University of Toronto partner to commercialize medical AI

Posted on August 2, 2023 (March 7, 2024) by Ricky

August 2, 2023 – FACIT and T-CAIREM announce partnership to commercialize medical artificial intelligence (AI) innovations. The partners intend to harness both T-CAIREM’s innovative translational research in AI and FACIT’s unique commercialization-venture model to build the next generation of Ontario biotechnology companies. The joint mission will accelerate the benefits of AI research to support patients battling cancer.

FACIT applauds quizartinib approval: a success for leukemia patients and Canadian cancer research translation

Posted on July 24, 2023 (November 2, 2023) by Ricky

July 24, 2023 – The U.S. FDA announced the approval of quizartinib, an important new therapy for patients with leukemia. This global effort to impact patients in need is to be celebrated while recognizing the contributions from across the Canadian health R&D ecosystem to reach this significant milestone that will now make a difference for patients.

FACIT founded Turnstone Biologics debuts on Nasdaq market

Posted on July 21, 2023 (November 1, 2023) by Ricky

July 21, 2023 – FACIT congratulates Turnstone Biologics on the announcement of their upsized initial public offering (IPO) and debut on the Nasdaq market.

From Idea to Start up: FACIT President’s interview with Amanda Lang

Posted on May 1, 2023 (September 25, 2023) by Ricky

May 1, 2023 – Watch FACIT President Dr. David O’Neill’s interview with Amanda Lang, host of Taking Stock on BNN Bloomberg. The episode, titled From Idea to Start up, originally aired on April 28, 2023. This was part of a special series about innovation in Canada and some of the challenges and opportunities. FACIT was featured as a “success

FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies

Posted on April 25, 2023 (July 24, 2023) by Ricky

April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.

New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition

Posted on March 31, 2023 (September 25, 2023) by nicole

March 31, 2023 – The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.

FACIT generates $1.5 billion in follow-on investment

Posted on March 29, 2023 (January 8, 2024) by nicole

March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

Posted on March 23, 2023 (May 8, 2023) by nicole

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.

Registration is now open for FACIT Falcons’ Fortunes pitch competition and reception

Posted on February 21, 2023 (April 28, 2023) by nicole

February 21, 2023 – This year marks the 10th anniversary of the FACIT Falcons’ Fortunes pitch competition! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.

FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund

Posted on June 23, 2020 (April 9, 2024) by jeremy

June 23, 2020 – June 23, 2020 – FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.